Follicular lymphoma is a very diverse disease, and decisions to treat in the frontline are made based on histology, disease burden and patient symptoms. The general approach should be a ...

Currently, prognosis in patients with FL is assessed using clinical scores such as the Follicular Lymphoma International Prognostic Index (FLIPI), which incorporates age, disease stage ...

Progression Within 24 Months Predicts Poorer Survival Following Relapse or Progression in Follicular Lymphoma Patients with FL who experience disease progression within 24 months of first-line ...

Because both of these cancers are typically slow-growing, both trials looked at overall response and complete response rates rather than survival rates. For the follicular lymphoma trial ...

Follicular lymphoma is the second most common form ... and it has a five-year survival rate of only 20% for patients in the third line and later. The new use is the third for Kymriah ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the CD19-directed CAR T cell therapy, which is already approved in the EU for certain lymphomas, be authorised to treat ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

(NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new collaboration with the Institute for Follicular Lymphoma ...